- Home
- RNR vs EXEL Comparison
RNR vs EXEL Comparison
Compare RNR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNR
- EXEL
- Stock Information
- Founded
- RNR 1993
- EXEL 1994
- Country
- RNR Bermuda
- EXEL United States
- Employees
- RNR N/A
- EXEL N/A
- Industry
- RNR Property-Casualty Insurers
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNR Finance
- EXEL Health Care
- Exchange
- RNR Nasdaq
- EXEL Nasdaq
- Market Cap
- RNR 12.3B
- EXEL 11.1B
- IPO Year
- RNR 1995
- EXEL 2000
- Fundamental
- Price
- RNR $267.23
- EXEL $43.25
- Analyst Decision
- RNR Hold
- EXEL Buy
- Analyst Count
- RNR 14
- EXEL 24
- Target Price
- RNR $287.08
- EXEL $44.73
- AVG Volume (30 Days)
- RNR 519.1K
- EXEL 3.2M
- Earning Date
- RNR 10-28-2025
- EXEL 11-04-2025
- Dividend Yield
- RNR 0.60%
- EXEL N/A
- EPS Growth
- RNR N/A
- EXEL 53.55
- EPS
- RNR 34.70
- EXEL 2.38
- Revenue
- RNR $12,214,870,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- RNR N/A
- EXEL $9.14
- Revenue Next Year
- RNR N/A
- EXEL $12.51
- P/E Ratio
- RNR $7.69
- EXEL $18.34
- Revenue Growth
- RNR N/A
- EXEL 9.93
- 52 Week Low
- RNR $219.00
- EXEL $31.90
- 52 Week High
- RNR $290.78
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- RNR 62.78
- EXEL 67.44
- Support Level
- RNR $263.34
- EXEL $39.83
- Resistance Level
- RNR $269.82
- EXEL $41.55
- Average True Range (ATR)
- RNR 6.28
- EXEL 1.38
- MACD
- RNR 1.84
- EXEL 0.52
- Stochastic Oscillator
- RNR 82.60
- EXEL 99.73
About RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.